- Home
- BJRI vs ALLO Comparison
BJRI vs ALLO Comparison
Compare BJRI & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BJRI | ALLO |
|---|---|---|
| Founded | 1978 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 884.0M | 738.4M |
| IPO Year | 1996 | 2018 |
Fundamental Metrics
Financial Performance| Metric | BJRI | ALLO |
|---|---|---|
| Price | $46.24 | $2.24 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 15 |
| Target Price | ★ $42.88 | $8.35 |
| AVG Volume (30 Days) | 307.4K | ★ 5.9M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 208.57 | 34.09 |
| EPS | ★ 0.41 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $4.71 | N/A |
| Revenue Next Year | $3.89 | $142,416.42 |
| P/E Ratio | $109.61 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $28.46 | $0.99 |
| 52 Week High | $47.02 | $4.46 |
Technical Indicators
Market Signals| Indicator | BJRI | ALLO |
|---|---|---|
| Relative Strength Index (RSI) | 74.94 | 53.28 |
| Support Level | $33.60 | $2.12 |
| Resistance Level | N/A | $2.39 |
| Average True Range (ATR) | 1.55 | 0.14 |
| MACD | 0.39 | 0.01 |
| Stochastic Oscillator | 94.03 | 73.64 |
Price Performance
Historical ComparisonAbout BJRI BJ's Restaurants Inc.
BJ's Restaurants Inc is involved in the business of owning and operating restaurants. The company operates in a single operating segment that is full-service company-owned restaurants. It has geographic presence only in the United States of America.
About ALLO Allogene Therapeutics Inc.
Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).